- July 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC") , a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has received its production run of approximately 20,000 units of its BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate
TB-500 is a synthetic derivative of thymosin beta 4, an endogenous peptide present in the thymus gland
Real-time monitoring enables healthcare providers to adjust drug dosages or introduce combination therapies promptly, thereby maintaining disease control without requiring aggressive or frequent interventions
Capsules are simpler and more consistent
Migliora lapporto sanguigno e riduce linfiammazione follicolare, supportando modelli sperimentali volti a invertire lassottigliamento dei capelli o a promuovere la rigenerazione del cuoio capelluto
Monitoring: Regular clinical follow-up ensures any adverse effects are detected early and protocols are adjusted accordingly